Paper
24 March 2023 Research progress on familial medullary thyroid cancer
Yuxin Chen
Author Affiliations +
Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126115A (2023) https://doi.org/10.1117/12.2669400
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom
Abstract
Familial medullary thyroid carcinoma is a malignant neurosecretory tumor originating from C cells. It is an autosomal dominant disease, belonging to the branch of hereditary thyroid cancer. At present, the academic understanding of FMTC is deeply into the gene level. Studies show that the point mutation of RET gene is the genetic basis of the pathogenesis of FMTC, and can be used for personalized diagnosis and treatment of patients. Clinically, genetic testing, imaging testing, serum Ctn level detection and other methods are usually applied to diagnose suspected cases. At the same time, surgery is the most effective treatment for FMTC, including preventive surgery and therapeutic surgery. This paper reviews the related research results of FMTC from the perspectives of clinical manifestations, genetic mechanisms, and therapeutic approaches, aiming to comprehensively decipher the development process and current status of this field.
© (2023) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Yuxin Chen "Research progress on familial medullary thyroid cancer", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126115A (24 March 2023); https://doi.org/10.1117/12.2669400
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Resolution enhancement technologies

Thyroid

Genetics

Tumors

Diseases and disorders

Surgery

Cancer

Back to Top